For Emergency Use Authorization. See country-specific product labeling for regulatory status. Others Country Specific Labeling cobas SARS-COV-2 Test 6800-8800 cobas® SARS-COV-2 For use under Emergency Use Authorization (EUA) RMD-6800-8800-SARS-003 Qualitative assay for use on the cobas® 6800/8800 systems 09 343 733 190 9 343 733 190 09343733190 9343733190 09343733190 KIT COBAS 6800/8800 SARS-COV-2 480T cobas SARS-COV-2 00875197006681 Reagents, kits 1 kit 480 tests true cobas® SARS-CoV-2 for use on the cobas® 6800/8800 Systems is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in healthcare provider-instructed self-collected anterior nasal (nasal) swab specimens (collectedon site), and healthcare provider-collected nasal, nasopharyngeal and oropharyngeal swab specimens collected from any individuals, including those suspected of COVID-19 by their healthcare provider,and those without symptoms or other reasons to suspect COVID-19. cobas® SARS-CoV-2 is for use only under Emergency Use Authorization (EUA) in laboratories certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high or moderate complexity tests.This test is also intended for the qualitative detection of nucleic acids from SARS-CoV-2 in pooled samples containing up to and including six individual samples from healthcare provider-instructed self-collected nasal swab specimens (collected on site), or healthcare provider-collected nasal, nasopharyngeal, and oropharyngeal swab specimens. Negative results from pooled samples should be treated as presumptive and, if inconsistent with clinical signs and symptoms or necessary for patient management, pooled samples should be tested individually. Specimens included in pools with a positive or presumptive positive result must be tested individually prior to reporting a result. Specimens with low SARS-CoV-2 RNA concentrations may not be detected in sample pools due to the decreased sensitivity of pooled testing. Testing of pooled samples is limited to laboratories certified under CLIA, 42 U.S.C. §263a, that meet requirements to perform high complexity tests.Results are for the detection of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses.Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, recent exposures and epidemiological information. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities. cobas® SARS-CoV-2 is intended for use by qualified clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and on the use of the cobas® 6800/8800 Systems. cobas® SARS-CoV-2 is only for use under the Food and Drug Administration’s Emergency Use Authorization. en cobas® SARS-CoV-2 is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The cobas® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software, which assigns test results for all tests. Results can be reviewed directly on the system screen, and printed as a report.Nucleic acid from patient samples and added internal control RNA (RNA IC) molecules are simultaneously extracted. Nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris and potential PCR inhibitors, are removed with subsequent wash steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature. External controls (positive and negative) are processed in the same way with each cobas® SARS-CoV-2 run.Selective amplification of target nucleic acid from the sample is achieved by the use of target-specific forward and reverse primers for ORF1 a/b non-structural region that is unique to SARS-CoV-2. Additionally, a conserved region in the structural protein envelope E-gene were chosen for pan-Sarbecovirus detection. The pan-Sarbecovirus detection sets will also detect SARS-CoV-2 virus.Selective amplification of RNA Internal Control is achieved by the use of non-competitive sequence specific forward and reverse primers which have no homology with the coronavirus genome. A thermostable DNA polymerase enzyme is used for amplification.The cobas® SARS-CoV-2 master mix contains detection probes which are specific for the coronavirus type SARS-CoV-2, members of the Sarbecovirus subgenus, and the RNA Internal Control nucleic acid. The coronavirus and RNA Internal Control detection probes are each labeled with unique fluorescent dyes that act as a reporter. Each probe also has a second dye which acts as a quencher. When not bound to the target sequence, the fluorescent signals of the intact probes are suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage of the probe by the 5' to 3' exonuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye increases concomitantly. Each reporter dye is measured at defined wavelengths, which enables simultaneous detection and discrimination of the amplified coronavirus target and the RNA Internal Control. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). Any contaminating amplicons from previous PCR runs are destroyed by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR mix, when heated in the first thermal cycling step. However, newly formed amplicons are not destroyed since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C. en

cobas® SARS-COV-2 Test

Qualitative assay for use on the cobas^® 6800/8800 Systems
For use under the Emergency Use Authorization (EUA) only
For in vitro diagnostic use

Country Specific Labeling

Reliable solutions for emergency situations

The cobas® SARS-CoV-2 Test provides reliable and high-quality results for clinical decision-making for patients with suspected COVID-19 (coronavirus) infection. The cobas® SARS-CoV-2 Test is a qualitative assay that allows the detection of nucleic acids in samples from patients who meet COVID-19 (coronavirus) clinical and/or epidemiological criteria. The tests are for use on the automated, high throughput cobas® 6800/8800 Systems under Emergency Use Authorization.

Features and Benefits of the cobas®SARS-CoV-2 Test (for the COVID-19 Coronavirus)

The cobas® SARS-CoV-2 Test is a single-well dual target assay, which includes both specific detection of SARS-CoV-2 (COVID-19 Coronavirus) and pan-sarbecovirus detection for the sarbecovirus subgenus family that includes SARS-CoV-2. The assay has a full-process negative control, positive control and internal control.

Accuracy

Dual target assay, specific target unique to SARS-Cov-2 (COVID-19 Coronavirus) along with a conserved region of the E-gene

Simplicity

Ready to use reagents and controls minimize variability

Specificity

Full-process controls with negative, positive and internal controls

Throughput

The systems provide up to 96 results in about three hours and a total of 384 results for the cobas® 6800 System and 1056 results for the cobas® 8800 System in 8 hours

Contamination control

A fully enclosed automated system with air lock doors and HEPA filtration

Hands-on Time

With only 3 manual interactions, up to 8 hours of walk-away time

Related Products

cobas® 6800 system

cobas® 8800 system

Would you like to know more about the cobas® SARS-COV-2 Test?

Please submit your information in the following form to be contacted by a Roche representative with more details.

Related Information

Patient fact sheet

SARS-CoV-2 (COVID-19 Coronavirus)*

Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). The novel coronavirus (SARS-CoV-2, also known as COVID-19) is a new strain which has not previously been identified in humans.

Signs of infection include respiratory symptoms such as cough, shortness of breath, difficulty breathing and fever. In more severe cases, pneumonia, severe acute respiratory syndrome, kidney failure and death can occur.

To control the spread of the infection, WHO recommends vaccination, social distancing, wearing masks when distancing is not possible, regular hand washing and avoiding close contacts with anyone showing symptoms of respiratory illness.

* Source: https://www.who.int/westernpacific/health-topics/detail/coronavirus. Accessed 2.14.2024.

Intended Use

FDA-Emergency Use Only

cobas® SARS-CoV-2 for use on the cobas® 6800/8800 Systems is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 inhealthcareprovider-instructed self-collectedanteriornasal(nasal)swab specimens (collectedon site), andhealthcare provider-collectednasal,nasopharyngeal, and oropharyngealswab specimenscollectedfromanyindividuals, including those suspected of COVID-19 by their healthcare provider,and those without symptoms or other reasons to suspect COVID-19. cobas® SARS-CoV-2 is for use only under Emergency Use Authorization (EUA)in laboratoriescertified underClinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements toperform high or moderatecomplexity tests.

This test is also intended for the qualitative detection of nucleic acids from SARS-CoV-2 in pooled samples containing up to and including six individual samples fromhealthcare provider-instructed self-collected nasal swab specimens (collected on site), or healthcare provider-collected nasal, nasopharyngeal, and oropharyngeal swab specimens. Negative results from pooled samples should be treated as presumptive and, if inconsistent with clinical signs and symptoms or necessary for patient management,pooled samples should be tested individually.Specimens included in pools with a positive or presumptive positive result must be tested individually prior to reporting a result. Specimens with low SARS-CoV-2 RNA concentrations may not be detected in sample pools due to the decreased sensitivity of pooled testing. Testing of pooled samples is limited to laboratories certified under CLIA, 42 U.S.C. §263a, that meet requirements to perform high complexity tests.

Results are for the detection of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable inrespiratoryspecimens duringthe acute phase ofinfection.Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history,recent exposuresand epidemiological information. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities. cobas ® SARS-CoV-2 is intended for use byqualifiedclinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR andon the use of the cobas ® 6800/8800 Systems. cobas ® SARS-CoV-2 is only for use under the Food and Drug Administration’s Emergency Use Authorization.

Registration Status

FDA-Emergency Use Authorization

In the United States:
- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization
of the emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorization is terminated or revoked sooner

Overview

Ordering information

Technical documents

Document repository

Technical documents

User profile

Select your user profile

cobas® SARS-COV-2 Test